Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes

Author
Cox, Amanda J., Pyne, D, Saunders, P, Fricker, P

Published
2010

Journal Title
British Journal of Sports Medicine

DOI
https://doi.org/10.1136/bjsm.2007.044628

Copyright Statement
Copyright remains with the authors 2010. The attached file is reproduced here in accordance with the copyright policy of the publisher. For information about this journal please refer to the journal's website or contact the authors.

Downloaded from
http://hdl.handle.net/10072/61538
Oral administration of the probiotic *Lactobacillus fermentum* VRI-003 and mucosal immunity in endurance athletes

A J Cox,¹,² D B Pyne,¹,³ P U Saunders,¹ P A Fricker³,⁴

**ABSTRACT**

Objective To evaluate the ability of a probiotic *Lactobacillus fermentum* VRI-003 (PCC) to enhance the mucosal immune system of elite athletes.

Design and setting A double-blind, placebo-controlled, crossover trial was conducted over a 4-month period of winter training.

Participants 20 healthy elite male distance runners.

Interventions PCC was given at a daily dose of $1.2 \times 10^6$ as a freeze-dried powder in gelatin capsules. Placebo capsules contained an inert excipient.

Main outcome measures Treadmill performance (monthly), mucosal and systemic immunity (monthly), training (daily) and illness (daily) were assessed. Serum cytokine levels, salivary IgA levels and incidence, duration and severity of respiratory tract infections were measured.

Results Subjects reported less than half the number of days of respiratory symptoms during PCC treatment (30 days) compared with placebo (72 days, $p<0.001$). Illness severity was also lower for episodes occurring during the PCC treatment ($p = 0.06$). There were no significant differences in the mean change in salivary IgA and IgA1 levels, or in interleukin (IL)4 and IL12 levels, between treatments. However, PCC treatment elicited a twofold ($p = 0.07$) greater change in whole-blood culture interferon gamma (IFNγ) compared with placebo. No substantial changes in running performance measures were seen over the study period.

Conclusions Prophylactic administration of PCC was associated with a substantial reduction in the number of days and severity of respiratory illness in a cohort of highly trained distance runners. Maintenance of IFNγ levels may be one mechanism underpinning the positive clinical outcomes.

Some endurance athletes undergoing strenuous training have an increased susceptibility to upper respiratory tract infection (URTJ) as a result of exercise-induced immunosuppression.¹ Several studies have demonstrated that the concentration and flow rate of secretory immunoglobulin A (SIgA), the major effector of host resistance to URTI, decreases after intense endurance exercise.¹⁻⁴ Gleeson and colleagues have shown a substantial correlation between a decrease in salivary IgA (particularly salivary IgA1) during training,³ and an increase in the number of respiratory infections in elite athletes. Since stress affects the levels of total salivary IgA measurement of salivary IgA subclasses may have value in quantifying the risk of infection in elite athletes.⁵ Given these observations, there is both clinical and theoretical interest in understanding the relationships between exercise, training, immune function and the practical intervention strategies to maintain immunocompetence in athletes undertaking intensive training programmes.

The efficacy of probiotics (lactic acid bacteria, which when ingested provide positive health benefits) in the treatment of gastrointestinal disease is well established. Several clinical studies have shown that certain probiotics may be useful in treating a variety of diarrhoeal disorders, including *Clostridium difficile* diarrhea, antibiotic-associated diarrhoea, *Rotavirus* diarrhoea, and traveller’s diarrhoea.⁶⁻⁷ There is also evidence that probiotics stimulate mucosal immune function in addition to their primary role in intestinal health. Lactic acid bacteria are reported to have a wide range of effects on the immune system, including augmentation of phagocytic function in neutrophils, monocytes, macrophages and natural killer cells.⁸ Specific immune responses, both humoral and cellular, may also be enhanced by administration of lactobacilli.⁹ Administration of *Lactobacillus* to children attending day care centres elicited a moderate reduction in the number of respiratory infections.¹⁰ An initial study by our research group examined the clinical and immunological consequences of probiotic administration in habitual exercisers. These subjects were patients at a fatigue outpatient clinic rather than healthy well-performing athletes.¹¹ Administration of the probiotic corrected a deficiency in the level of interferon γ (IFNγ). The only other study of probiotics in athletes reported that probiotic administration shortened the duration of gastrointestinal symptom episodes in marathon runners but had no effect on the incidence of respiratory infections or gastrointestinal symptoms.¹²

Another probiotic strain *Lactobacillus fermentum* is a potentially useful nutritional intervention in a sports medicine setting. Preliminary research in mice highlights the potential for enhancement of gut immunity with *L. fermentum* administration.¹³ *L. fermentum* colonises the gastrointestinal tract of healthy volunteers after a single dose¹⁴ and adheres to Peyer’s patches, the immunosampling site in the small intestine.¹⁵ We sought to extend these initial studies into healthy human subjects. The aim of this study was to determine whether *L. fermentum* enhances immunological protection in a group of healthy well-trained athletes, and whether any induced immunological changes correspond with a change in the self-reported incidence of illness and infection. We hypothesised that oral...
administration of the *L. fermentum* might trigger a protecting mucosal immune response and reduce the incidence, severity and/or duration of respiratory illness in endurance athletes.

**SUBJECTS AND METHODS**

**Study subjects and design**

Twenty highly-trained distance runners, competing in events ranging from 800 m to the marathon (42.2 km), were recruited into the 14-week study. The mean (SD) age of the study cohort at recruitment was 27.3 (6.4) years. Other characteristics (mean (SD)) of the group at recruitment were: height 1.80 (0.06) m; mass 66.7 (6.0) kg; percentage muscle mass 46.6 (1.5)%; percentage fat mass 8.1 (0.9)%; and *VO*₂*max* 67.1 (4.5) ml/kg/min. The study protocol was approved by the Ethics Committee of the Australian Institute of Sport in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

At recruitment a sports doctor recorded a medical history for each subject and baseline measures of immune function were taken. The study was undertaken using a double-blind, placebo-controlled, crossover design with subjects randomly assigned to placebo or treatment groups by a third party independent of the research team. The research team remained unaware of these allocations until completion of the study. After recruitment, subjects completed an initial treatment month (28 days) receiving either *L. fermentum* or placebo. A washout month (28 days) followed the completion of the first treatment month. Previous studies have established that the normal time course for passage of probiotic bacteria through the gastrointestinal tract is 3–8 days. Subjects were then crossed into the opposing arm of the study for a second treatment month (28 days), so that those receiving *L. fermentum* VRI-003 as the first treatment received the placebo as the second treatment and vice versa. Subjects were monitored for an additional fortnight (referred to as “follow-up”) after completion of the second treatment.

During each treatment month (28 days) subjects were required to take three capsules, twice daily of either the probiotic or placebo with food. The probiotic, *L. fermentum* VRI-003 (PCC), contained a minimum of two billion of *Lactobacillus fermentum* viable organisms per capsule at the end of the specified shelf life. The total daily dose of six capsules provided 1.2 x 10⁹ colony-forming units. The probiotic is available to healthcare practitioners as Prografim (Probiotics Pty Ltd, Perth, Australia). The placebo was identical to the *L. fermentum* VRI-003 except that the *Lactobacillus* was replaced with microcrystalline cellulose. Subjects maintained daily training and illness records, provided weekly saliva and monthly blood samples, and completed monthly treadmill testing in the laboratory. Subjects were also required to refrain from consuming yoghurt and yoghurt-based products for the duration of the study.

**Participant compliance**

All 20 subjects completed the study. Subjects were asked to score their compliance with the medication schedule on a five-point scale (1, low compliance; 5, complete compliance). The mean levels of compliance during the first and second treatment months were 4.1 and 3.9, respectively. The respective compliance scores were 3.9 during the *L. fermentum* VRI-003 treatment and 4.2 during the placebo treatment.

**Training and performance measures**

Subjects recorded details of their training during the study. For each session, training mileage (km/wk), duration (h/wk) and intensity (scored on a 1–5 scale: 1, easy; 5, maximal) were recorded. At the start of the study period and at the end of each study month subjects completed a treadmill running test. This test involved continuous incremental running of three 4-minute periods at 14, 16 and 18 km/h at 0% gradient. After a 2-minute break the subject started running again at a speed of 18 km/h that was increased by 1 km/h each minute for 3 minutes all at 0% gradient. Beyond this point the speed was maintained at 20 km/h but the gradient increased by 1% per minute until the subject reached volitional exhaustion. Heart rate was recorded continuously with expired ventilation samples collected for determination of oxygen uptake. Improvements or otherwise in endurance fitness were indicated by the maximal oxygen uptake and performance level (running velocity and gradient) reached at the end of the incremental treadmill test.

**Patterns of illness**

Subjects kept a daily symptom log to record any symptoms of illness (and side effects) including episodes of sore throat, cough, runny nose, sneezing (URTI), chest congestion (lower respiratory illness (LRI)), headache, fever, muscle or joint aches, abdominal pain, cramping, and/or loss of appetite. Subjects rated the severity of the symptoms as mild (normal training), moderate (modified training) or severe (trained discontinued) (scored 1–3, respectively). Dietary supplements and drugs (prescribed and over-the-counter) that might have influenced the underlying immune function or exercise performance, or both, were also recorded. Illness logs were reviewed by a sports doctor for coding of reported episodes of illness. At the end of each treatment subjects were asked to score their general health on a five-point scale (1, frequent illness; 5, no illness). Where possible, acute presentation for doctor verification and documentation was undertaken.

**Measures of mucosal immunity**

Whole, mixed, unstimulated saliva was collected by passive drool or gentle spitting and stored at −80°C until analysis for IgA, IgA1 and salivary albumin. SlgA concentrations in saliva were measured using an in-house ELISA assay as previously described. All samples were assayed in triplicate in conjunction with high, moderate and low positive controls and saliva from an IgA-deficient person used as a negative control. SlgA concentrations were determined by standardisation against Human Serum Protein Calibrator (Dako, Glostrup, Denmark) referenced against BCR CRM470. The interassay variability for the high, moderate and low positive controls was 11.4%, 11.7% and 8.9%, respectively.

**Measures of systemic immunity**

Upon recruitment and at the completion of treatment 1, washout and treatment 2, subjects provided a blood sample for establishment of whole-blood cultures and determination of interleukin (IL)4 (Th2 secreted), IL12 (macrophage secreted) and IFNγ (Th1 secreted) concentrations. Blood was collected from the antecubital vein using standard venepuncture techniques. Whole-blood cultures were established at 37°C and 5% CO₂ for 48 hours; culture supernatants were then collected and cytokine concentrations determined using in-house ELISA methods as previously described. For the IL4 ELISA the interassay variability for high and low controls was 9.8% and 4.2 during the placebo treatment.
treadmill performance time (min) averaged for both treatments

L fermentum  placebo treatments

Differences in the number, duration and intensity of symptoms

Table 1 shows the mean (SD) training mileage (km/wk), duration (h/wk) and intensity (scored 1–5). The mean training mileage was similar for both treatment groups at ~100 km/wk. Similarly, there were no significant differences in training duration or intensity between treatments across the duration of the study (table 1). The \( \text{VO}_{2\text{max}} \) (ml/kg/min) and maximum treadmill performance time (min) averaged for both treatments are also shown in Table 1. The mean \( \text{VO}_{2\text{max}} \) and maximum treadmill performance time were not substantially different between subjects receiving \( L \) fermentum and placebo treatments.

Five subjects (25%) were free of illness over the course of the study. Symptoms of URTI and LRI accounted for 58% of all reported illness episodes in the other 15 subjects. Other illness symptoms were verified as influenza, gastrointestinal illness or a skin condition. Half as many episodes of URTI and LRI symptoms were reported during the \( L \) fermentum VRI-003 treatment compared with placebo (table 2); however, the mean episode duration did not differ between probiotic (7.5 days) and placebo (8 days) treatments. Similarly, fewer subjects reported respiratory symptoms during the \( L \) fermentum VRI-003 treatment. The number of total illness days during \( L \) fermentum VRI-003 treatment (n = 30 days) was significantly lower (<0.001) than during placebo treatment (n = 72 days). The mean severity of respiratory illness occurring during \( L \) fermentum treatment was marginally lower than that recorded during placebo treatment.

Patterns of mucosal immunity

\( L \) fermentum and placebo treatments had no substantial effects on salivary IgA and salivary IgA1 concentrations (table 3). There was a modest increase in IgA after \( L \) fermentum treatment and a trivial change after placebo treatment. Given the large variability in the within-subject changes with the experimental treatments the overall effect of \( L \) fermentum treatment on salivary IgA was unclear. \( L \) fermentum treatment elicited a modest increase in salivary IgA1 with a trivial change after placebo. The overall effect of \( L \) fermentum on salivary IgA1 was a small 26% increase compared with placebo, although this difference failed to reach statistical significance.

Patterns of systemic immunity

Table 4 shows the effects of \( L \) fermentum and placebo treatments on whole-blood culture cytokine secretions. We report the baseline values at the start of each treatment, the percentage (%) change in cytokine concentration after 28 days of supplementation, the percentage difference in the change in mean cytokine concentrations, and the magnitude (effect size) of this difference. Large between-subject variability (estimated as the coefficient of variation) was evident in the concentrations of all three cytokines under investigation (at baseline IFN\( \gamma \) 25%, IL4 112% and IL12 118%). There was only a trivial difference in the mean change in IL4 concentration after the experimental treatments. After \( L \) fermentum treatment there was a modest increase in IFN\( \gamma \), but a modest decrease after placebo treatment. The overall effect was a twofold greater increase in IFN\( \gamma \) for the \( L \) fermentum treatment: essentially this indicates that \( L \) fermentum was effective in attenuating the reduction in IFN\( \gamma \) observed in the placebo condition. Similarly, \( L \) fermentum showed some potential for attenuating reductions in IL12 with a small 36% difference in the effect of the experimental treatments.

Table 1 The training mileage, duration, intensity, \( \text{VO}_{2\text{max}} \), and maximum treadmill time recorded from the cohort during each of the treatments

<table>
<thead>
<tr>
<th>Mileage (km/wk)</th>
<th>Duration (h/wk)</th>
<th>Intensity (scored 1–5)</th>
<th>( \text{VO}_{2\text{max}} ) (ml/kg/min)</th>
<th>Treadmill time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>107 (37)</td>
<td>8.2 (2.8)</td>
<td>2.1 (0.5)</td>
<td>67.1 (4.5)</td>
<td>5.2 (1.6)</td>
</tr>
<tr>
<td><strong>L fermentum</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>101 (42)</td>
<td>7.6 (3.2)</td>
<td>2.4 (0.6)</td>
<td>69.5 (3.8)</td>
<td>5.6 (1.4)</td>
</tr>
<tr>
<td><strong>Placebo</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99 (46)</td>
<td>7.5 (3.4)</td>
<td>2.4 (0.5)</td>
<td>68.0 (4.6)</td>
<td>5.3 (1.8)</td>
</tr>
<tr>
<td><strong>p Value</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.96</td>
<td>0.98</td>
<td>0.58</td>
<td>0.19</td>
<td>0.84</td>
</tr>
</tbody>
</table>

Results expressed as the mean (SD). Intensity of the scored 1–5 where 1 is the least and 5 the maximum.

All reported p values are based on comparisons between probiotic and placebo treatments.

Differences in the frequency of illness measures recorded during probiotic and placebo treatments

Table 2 Differences in the number, duration and intensity of symptoms of common upper respiratory tract infection (URT) and lower respiratory illnesses (LRI) in highly trained distance runners between probiotic and placebo treatments

<table>
<thead>
<tr>
<th>Illness (URT and LRI)</th>
<th>L fermentum</th>
<th>Placebo</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Episodes (n)</td>
<td>4</td>
<td>9</td>
<td>0.24</td>
</tr>
<tr>
<td>Subjects reporting (n)</td>
<td>3</td>
<td>7</td>
<td>0.27</td>
</tr>
<tr>
<td>Symptom days (days)</td>
<td>30</td>
<td>72</td>
<td>~0.001</td>
</tr>
<tr>
<td>Mean episode severity (scored on a 1–3 scale)</td>
<td>1.0</td>
<td>1.7</td>
<td>0.06</td>
</tr>
</tbody>
</table>

Severity was rated on a 1–3 Likert scale where 1 = mild, 2 = moderate and 3 = severe symptoms.

Statistical analysis

Simple descriptive statistics are shown as mean (between-subject SD). Preliminary power analysis indicated that 16 subjects were required in a crossover design assuming a typical error of 12% for IFN\( \gamma \), a reference change of 50 pg/ml and a type 2 error rate of 20%. Mean effects of probiotic and placebo treatments and their 90% confidence limits were estimated with a spreadsheet via the unequal-variances \( t \)-statistic computed for change scores between pre- and post-tests of the two groups.\(^{22-25}\) Each subject’s change score was expressed as a percentage of baseline score by analysis of log-transformed values, in order to reduce bias arising from non-uniformity of error. Magnitudes of effect were classified according to the following criteria: 0.00–0.19 trivial, 0.20–0.59 small, 0.60–1.19 moderate, 1.20–1.99 large and >2.00 very large. An unclear effect was defined where the confidence limits of the effect spanned the range of substantially positive to substantially negative values. Comparison of the frequency of illness measures recorded during probiotic and placebo treatments was conducted using \( \chi^2 \) analysis, and illness severity scores were compared using a Mann–Whitney U test for non-parametric measures. Non-parametric statistical analyses were conducted with Statistica analytical software, version 6.0 (StatSoft Inc, OK, USA).

RESULTS

Patterns of training and performance

Table 1 shows the mean (SD) training mileage (km/wk), duration (h/wk) and intensity (scored 1–5). The mean training mileage was similar for both treatment groups at ~100 km/wk. Similarly, there were no significant differences in training duration or intensity between treatments across the duration of the study (table 1). The \( \text{VO}_{2\text{max}} \) (ml/kg/min) and maximum treadmill performance time (min) averaged for both treatments are also shown in Table 1. The mean \( \text{VO}_{2\text{max}} \) and maximum treadmill performance time were not substantially different between subjects receiving \( L \) fermentum and placebo treatments.

Five subjects (25%) were free of illness over the course of the study. Symptoms of URTI and LRI accounted for 58% of all reported illness episodes in the other 15 subjects. Other illness symptoms were verified as influenza, gastrointestinal illness or a skin condition. Half as many episodes of URTI and LRI symptoms were reported during the \( L \) fermentum VRI-003 treatment compared with placebo (table 2); however, the mean episode duration did not differ between probiotic (7.5 days) and placebo (8 days) treatments. Similarly, fewer subjects reported respiratory symptoms during the \( L \) fermentum VRI-003 treatment. The number of total illness days during \( L \) fermentum VRI-003 treatment (n = 30 days) was significantly lower (<0.001) than during placebo treatment (n = 72 days). The mean severity of respiratory illness occurring during \( L \) fermentum treatment was marginally lower than that recorded during placebo treatment.

Patterns of mucosal immunity

\( L \) fermentum and placebo treatments had no substantial effects on salivary IgA and salivary IgA1 concentrations (table 3). There was a modest increase in IgA after \( L \) fermentum treatment and a trivial change after placebo treatment. Given the large variability in the within-subject changes with the experimental treatments the overall effect of \( L \) fermentum treatment on salivary IgA was unclear. \( L \) fermentum treatment elicited a modest increase in salivary IgA1 with a trivial change after placebo. The overall effect of \( L \) fermentum on salivary IgA1 was a small 26% increase compared with placebo, although this difference failed to reach statistical significance.

Patterns of systemic immunity

Table 4 shows the effects of \( L \) fermentum and placebo treatments on whole-blood culture cytokine secretions. We report the baseline values at the start of each treatment, the percentage (%) change in cytokine concentration after 28 days of supplementation, the percentage difference in the change in mean cytokine concentrations, and the magnitude (effect size) of this difference. Large between-subject variability (estimated as the coefficient of variation) was evident in the concentrations of all three cytokines under investigation (at baseline IFN\( \gamma \) 25%, IL4 112% and IL12 118%). There was only a trivial difference in the mean change in IL4 concentration after the experimental treatments. After \( L \) fermentum treatment there was a modest increase in IFN\( \gamma \), but a modest decrease after placebo treatment. The overall effect was a twofold greater increase in IFN\( \gamma \) for the \( L \) fermentum treatment: essentially this indicates that \( L \) fermentum was effective in attenuating the reduction in IFN\( \gamma \) observed in the placebo condition. Similarly, \( L \) fermentum showed some potential for attenuating reductions in IL12 with a small 36% difference in the effect of the experimental treatments.

12.4%, respectively. For the IL12 ELISA the interassay variability was 8.4% and 9.7%, respectively. Similarly, the interassay variability for IFN\( \gamma \) was 3.9% and 11.9%, respectively.
Table 3 Mucosal immune concentrations (IgA and IgA1) measured in saliva at baseline and after each of the experimental treatments

<table>
<thead>
<tr>
<th>Measure</th>
<th>Treatment</th>
<th>Baseline (mg/ml)</th>
<th>Percentage change (± 90% CL)</th>
<th>Difference in mean % change (± 90%CL)</th>
<th>Effect size (descriptor)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgA</td>
<td><em>L. fermentum</em></td>
<td>56.0 (35.4)</td>
<td>29.0 ± 80.7</td>
<td>39.5 ± 61.8</td>
<td>0.59, unclear</td>
<td>0.24</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>69.2 (44.7)</td>
<td>−7.5 ± 58.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgA1</td>
<td><em>L. fermentum</em></td>
<td>94.5 (63.4)</td>
<td>21.3 ± 67.0</td>
<td>25.9 ± 34.3</td>
<td>0.53, small</td>
<td>0.19</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>92.7 (34.4)</td>
<td>−3.6 ± 64.6</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The magnitude of the difference in the change in means is shown. CL, confidence limits.

DISCUSSION

The most important finding of this study was a significant reduction in the number of days of respiratory illness symptoms, and a trend towards a lower severity of illness, during *L. fermentum* VRI-005 treatment compared with placebo. These positive clinical consequences provide evidence for the beneficial effects of daily prophylactic intervention with *L. fermentum* in a cohort of highly trained distance runners. An improvement in resistance to common illnesses constitutes an important benefit to elite athletes undertaking high-level training in preparation for national and international competitions. In combination with the recent report that *L. rhamnosus* supplementation reduced the duration of gastrointestinal symptoms in marathon runners in the 2 weeks after the race, our findings point to the potential benefits of this form of nutritional intervention.

The beneficial effect of probiotic administration on the incidence of respiratory illness is possibly linked to an enhancement of systemic immunity. We observed that the IFNγ (Th1 secreted) response was moderately higher with the probiotic treatment than with placebo. Increased IFNγ concentration implies an increase in cell-mediated activities. Our observation is therefore consistent with the theory that *L. fermentum* induces a Th1 shift, although this assertion awaits experimental confirmation. Gleeson and Pyne reported a substantial correlation between a decrease in salivary IgA (particularly IgA1) during training, and an increase in number of respiratory illnesses in elite athletes. The subclass IgA2, induced by carbohydrates and lipid-containing antigens, also offers promise as a potential marker of mucosal immune disturbance. On this basis measurement of IgA subclasses, and their ratio, may have a predictive value for infection risk in elite athletes. We observed higher IgA1 in athletes taking the probiotic, but these differences were modest and influenced by the substantial within- and between-subject variation. Future studies are required to confirm these preliminary findings.

The possibility that probiotic administration can induce a protective immune response in the respiratory tract is consistent with the findings of Gluck and Gebbers. These investigators showed that oral ingestion of a probiotic beverage containing a mixture of *Lactobacillus GG*, *Streptococcus thermophilus*, *Bifidobacterium* and *Lactobacillus acidophilus* elicited a substantial 19% reduction in the occurrence of nasal pathogenic bacteria. The probiotic effects were primarily exerted on Gram-positive bacteria, which decreased significantly in number, pointing to links between lymphoid tissue in the gut and the upper respiratory tract. This finding is consistent with the concept of immune cell trafficking from one mucosal site to another in the body. Stimulation at one site, such as in the intestine, can result in effects detectable at another site, such as the respiratory tract. Similarly, administration of *Lactobacillus GG* to children in day care centres decreased the incidence of respiratory tract infections.

After colonisation of the gastrointestinal tract, the mechanisms by which probiotic bacteria mediate enhanced immunity remain unclear, with both humoral and cellular mechanisms under investigation. While it is not possible to draw definitive conclusions on the mechanisms by which probiotic bacteria enhance immune function from the findings of the current study, several of the trends seen are consistent with other published reports. Further investigations are required to determine whether the beneficial effects of probiotic administration can translate to both the general public and specialised populations like elite athletes, clinical conditions, immunocompromised subjects, and military and industrial settings. Since different strains of *L. fermentum* have different immunostimulating ability, the present findings cannot be directly extrapolated to other strains of *L. fermentum* without further testing of each strain.

We conclude that oral administration of *L. fermentum* strain VRI-005 reduced the number of days during which athletes undergoing intensive training had respiratory illnesses, possibly

Table 4 Changes in whole-blood cytokine concentrations between *L. fermentum* and placebo treatments

<table>
<thead>
<tr>
<th>Measure</th>
<th>Treatment</th>
<th>Baseline (pg/ml)</th>
<th>Percentage change (± 90% CL)</th>
<th>Difference in mean % change (± 90%CL)</th>
<th>Effect size (descriptor)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFNγ</td>
<td><em>L. fermentum</em></td>
<td>310 (373)</td>
<td>118 ± 342</td>
<td>199 ± 171</td>
<td>0.81, moderate</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>524 (521)</td>
<td>−27 ± 303</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL4</td>
<td><em>L. fermentum</em></td>
<td>54.1 (39.3)</td>
<td>−12 ± 174</td>
<td>0.9 ± 70.9</td>
<td>0.01, trivial</td>
<td>0.98</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>46.7 (40.9)</td>
<td>−12 ± 247</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL12</td>
<td><em>L. fermentum</em></td>
<td>182 (246)</td>
<td>−3 ± 127</td>
<td>36.2 ± 38.7</td>
<td>0.40, small</td>
<td>0.12</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>168 (129)</td>
<td>−29 ± 67</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The magnitude of the difference in the change in means is shown. CL, confidence limits.
by stimulation of a protective immune response. The finding of clinical benefits with probiotic supplementation in a small cohort of physically fit subjects, provides the basis for further studies examining the beneficial effects of *L. fermentum* VRI-003 administration on immune function in both the general community and specific populations.

**Acknowledgements** We thank Dr Peter French and Dr Trish Conway of Probiomics Ltd for their intellectual input, contributions and assistance throughout the project. We also thank Dr David Abraham, Department of Sports Medicine, and Graeme Allbon, Department of Physiology, Australian Institute for Sport for their clinical and laboratory support. We acknowledge the assistance of Professor Maree Gleeson, University of Newcastle and Dr Margaret Dunkley, VRI BioMedical Ltd, for their comments on the experimental design.

**Funding** The study was funded by Probiomics Ltd (formerly VRI BioMedical Ltd) and by an AusIndustry RDST Grant awarded to VRI BioMedical. AJC was funded by VRI BioMedecal Ltd as the clinical trials coordinator for this project.

**Competing interests** None.

**Ethics approval** By the Ethics Committee of the Australian Institute of Sport in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

**REFERENCES**